Equities

Percheron Therapeutics Ltd

Percheron Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.092
  • Today's Change0.002 / 2.22%
  • Shares traded769.34k
  • 1 Year change+24.32%
  • Beta0.4521
Data delayed at least 20 minutes, as of Jun 14 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.

  • Revenue in AUD (TTM)624.51k
  • Net income in AUD-10.85m
  • Incorporated2000
  • Employees8.00
  • Location
    Percheron Therapeutics Ltd14 Wallace Avenue,, ToorakMELBOURNE 3142AustraliaAUS
  • Phone+61 39827-8999
  • Fax+61 39859-7701
  • Websitehttps://www.antisense.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Anteotech Ltd526.75k-11.46m51.83m40.00--9.71--98.40-0.0056-0.00560.00030.00220.0552--2.62---120.11-68.55-145.22-75.44-----2,176.15-1,432.10----0.1729---46.6511.41-18.08--25.84--
LTR Pharma Ltd-100.00bn-100.00bn54.21m----17.09----------0.0451----------------------------0.00---100.00---41.65------
Cynata Therapeutics Ltd436.25k-13.65m55.69m0.00--4.54--127.65-0.0873-0.08730.00270.06830.0257--4.26---80.33-38.07-87.15-41.10-----3,127.93-513.73----0.00---94.9619.81-162.20------
Vitura Health Ltd119.67m9.40m57.59m121.006.071.4715.230.48120.01650.01650.20990.06811.9811.2210.51989,034.2015.2515.2922.3021.0631.23--7.706.921.185,598.190.2359--75.16--128.31146.9554.86--
Inoviq Ltd751.54k-6.51m60.73m85.00--3.63--80.81-0.0708-0.07080.00820.1820.03392.100.873---29.33-47.68-32.18-50.7695.07---866.27-2,527.824.93--0.0332--119.59153.3150.71------
Neurotech International Ltd1.28m-4.98m62.06m----11.35--48.58-0.0058-0.00580.00150.00540.1826-0.11495.67---71.23-197.33-74.66-255.24100.0779.57-390.03-1,043.8818.35--0.00--106.2283.24-131.75------
Next Science Ltd33.43m-24.52m72.92m----3.77--2.18-0.106-0.1060.14280.06631.467.478.33---107.19-74.40-136.06-90.3173.2076.98-73.36-128.263.45-50.370.0698--89.3650.80-28.29---2.28--
Biome Australia Ltd10.24m-2.86m78.75m30.00--36.53--7.69-0.0141-0.01410.05060.01011.371.936.04341,434.70-38.27---74.60--61.29---27.97--0.9514-15.920.4032--73.58--32.20------
Paradigm Biopharmaceuticals Ltd8.67m-69.00m82.20m----2.44--9.49-0.2296-0.22960.02880.09620.1298--2.25---103.34-40.96-127.58-44.1399.87---796.30-466.85---348.760.0085--7.5825.42-32.26------
Percheron Therapeutics Ltd624.51k-10.85m82.94m8.00--5.04--132.81-0.0157-0.01570.00090.01820.0328--0.3224---56.94-72.09-66.58-81.73-----1,737.37-6,558.90----0.001--1,026.1672.03-95.81------
Actinogen Medical Ltd337.51k-14.87m85.83m----6.25--254.29-0.0073-0.00730.00020.00510.0211--0.7341---92.99-45.55-105.88-48.24-----4,405.86-5,369.76---294.930.0037--792.7431.88-13.21--166.95--
Argenica Therapeutics Ltd92.21k-4.67m86.79m----10.60--941.26-0.0511-0.05110.0010.06650.0109--0.6384---55.31---69.00-------5,067.62-----6,663.200.00--2,340.00---17.71------
PharmAust Limited1.85m-7.79m89.08m52.00--11.28--48.12-0.0236-0.02010.00550.020.1977--6.71---83.26-25.56-96.46-28.7820.0690.73-421.04-59.16---104.650.00---13.533.42-263.63---47.47--
Recce Pharmaceuticals Ltd6.81m-11.32m112.19m----209.73--16.47-0.0637-0.06370.03850.00261.68--52.84---279.04-110.82-985.91-139.61-----166.11-391.79---24.070.2712--39.5327.79-19.03---26.31--
Proteomics International LaboratoriesLtd1.44m-5.90m113.88m----19.89--78.81-0.0518-0.05180.01290.04370.1817--11.13---75.75-57.79-87.11-67.57-----416.78-229.69---283.470.0088---14.644.12-24.20--89.02--
Data as of Jun 14 2024. Currency figures normalised to Percheron Therapeutics Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

10.68%Per cent of shares held by top holders
HolderShares% Held
Platinum Investment Management Ltd.as of 24 Apr 202496.27m10.68%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.